Baird analyst Jack Allen lowered the firm’s price target on MiNK Therapeutics (INKT) to $4 from $8 and keeps an Outperform rating on the shares. The firm said the company announced 3Q24 financials and provided pipeline updates, which were generally in line with expectations.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue